Source - LSE Regulatory
RNS Number : 2091D
MGC Pharmaceuticals Limited
01 March 2022
 

 

MGC Pharmaceuticals Ltd.

Compliance Statement - Prior Share Issues, Admission to Trading

1 March 2022

ASX, LSE: MXC

 

 

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') advises that following the RNS releases dated 10 February 2022  and 16 February 2022 for prior share issues between the Company's LSE Listing on 9 February 2021 and the Placing undertaken in December 2021, it is now applying for the admission to the Financial Conduct Authority's Official List, and to trading on the Main Market of the LSE for 20,613,270 Fully Paid Ordinary Shares issued by the Company from the December 2021 Placing up to today. The Company is seeking admission to trading for these shares from 8:00am (GMT) on Friday 4 March 2022.

The Company advises that the details of the 20,613,270 shares for which these applications are being lodged are as follows:

1.

6/12/2021

750,000 shares issued as consideration for the extension of the maturity date of convertible notes issued by the Company.

2.

1/2/2022

1,440,117 shares issued as remuneration to an employee of the Company.

3.

1/2/2022

500,000 shares issued on the exercise of securities granted under the Company's Employee Share Scheme

4.

22/2/2022

17,923,153 shares issued as deferred purchase consideration to the vendors of MediCaNL Inc.

 

The Company confirms that listing applications for all past share issues have been dealt with as a result of the above applications filed with the FCA and LSE.  And advises that for future share issues by the Company, listing applications filed with the FCA and LSE, along with the requisite RNS release will be lodged at the time the shares are issued.

 

--Ends--

Authorised for release by the Chairman, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer

CEO & Managing Director

+61 8 6382 3390

info@mgcpharma.com.au

MGC Pharmaceuticals Ltd

David Lim

Company Secretary

+61 8 6382 3390

info@mgcpharma.com.au  

UK Broker - Turner Pope

Andy Thacker

+44 203 657 0050

info@turnerpope.com

UK PR Advisors - Tavistock

Charles Vivian / Tim Pearson

+44 207 920 3150

mgcpharma@tavistock.co.uk

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBKDBPDBKDDNK
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJBell logo

Related Charts

Mgc Pharmaceuticals Limited (MXC)

+0.30p (+1.43%)
delayed 10:22AM